<p>Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report</p>

Abstract

Background: COVID-19 (coronavirus disease 2019) has become a global public health emergency since patients were first detected in Wuhan, China, in December 2019. Currently, there are no satisfying antiviral medications and vaccines available. Case Presentation: We reported the treatment process and clinical outcome of a 48-yearold man critically ill COVID-19 patient who received transfusion of allogenic human umbilical cord mesenchymal stem cells (UC-MSCs). Conclusions: We proposed that UC-MSC transfusion might be a new option for critically ill COVID-19. Although only one case we were shown, more similar clinical cases are inquired for further evidence providing the potential effectiveness of UC-MSC treatment.

Intravenous Administration of Umbilical Cord Mesenchymal Stromal Cells in Advanced-stage Critical COVID-19: a Case Report

“…MSC-based therapy protocols to treat COVID-19 have been directed mainly to patients with moderate and severe clinical presentations [9][10][11][12][13][14][15][16][17][18]. Few numbers of studies included critically ill patients with COVID-19 under invasive mechanical ventilation [24][25][26].…”

“…Mesenchymal stromal cells (MSCs) have been evaluated in compassionate use or clinical trials to treat COVID-19 pneumonia [9][10][11][12][13][14][15][16][17][18]. The rationale is to direct the immunomodulatory properties of MSCs to control the hyperin ammatory state and improve respiratory function.…”

Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy

“…Supporting the possible implementation of MSC treatment in COVID-19, since the beginning of the outbreak four clinical studies and four case reports investigating MSC’s therapeutic potential (and their derived products) to treat COVID-19 patients have been performed and already published their results [ [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] ]. Moreover, several phase I or II clinical trials are currently ongoing ( www.clinicaltrials.gov ).…”

“…The patient was extubate 5 days after MSC infusion No major adverse effects were observed A control group was not included [ 11 ] Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study NA Spain AD-MSC ∼0.98 × 10 6 cells/kg G1: 2 G2: 1 G3: 3 IV G1: 10 G2: 2 G3: 1 Thirteen patient requiring intubation were treated with MSC and steroids 70 % of patients showed clinical ameliorations and 53 % were extubated MSC were able to modulate inflammation No major adverse effects were observed A control group was not included [ 10 ] Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report NA China UC-MSC 1 × 10 6 cells/Kg 1 IV 1 Clinical ameliorations and decrease inflammation were observed upon MSC transplantation. No major adverse effects were observed A control group was not included Most clinical trials include a control/placebo group except for the ones were this absence is mentioned.…”

“…Indeed, regardless of the organ, SARS-CoV-2 infection causes disseminated inflammatory reactions, so therapies that bear immunomodulatory effects are welcome to treat COVID-19. Corroborating this idea, several clinical trials using MSC or their derived products are now ongoing and eight clinical studies were already concluded and reported interesting results, as most COVID-19 patients recovered a few days after treatment [ [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] ]. However, only one of these studies incorporated appropriate control groups and a considerable number of patients.…”